Bio­gen lays out a plan to “stream­line” ops, add $400M to fund neu­ro­sciences R&D, new deals

Bio­gen saw its share price $BI­IB pop up more than 5% Tues­day morn­ing as the com­pa­ny re­port­ed sharply high­er rev­enue for Spin­raza, in­di­cat­ing that they have a ma­jor com­mer­cial hit on their hands. And CEO Michel Vounatsos is seiz­ing the mo­ment, out­lin­ing plans to in­vest hun­dreds of mil­lions more each year in its neu­ro­sciences R&D work as he plans to ful­fill a vow to make Bio­gen the lead­ing com­pa­ny in the field. Those plans in­clude late-stage ac­qui­si­tions and “deals of all sizes.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER